Cargando…
Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer
INTRODUCTION: Programmed death-ligand 1 (PD-L1) expression determined by immunohistochemistry is the most widely used biomarker for predicting response to immune checkpoint inhibitors. The characteristics of PD-L1 expression in tumor cells inside lymphovascular spaces are largely unknown. Although P...
Autores principales: | Yeh, Yi-Chen, Ma, Hsiu-Hsun, Chu, Ping-Yuan, Ho, Hsiang-Ling, Chou, Teh-Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250021/ https://www.ncbi.nlm.nih.gov/pubmed/35789791 http://dx.doi.org/10.1016/j.jtocrr.2022.100349 |
Ejemplares similares
-
Uterine adenosarcoma associated to lymphovascular emboli: a case report
por: Sakr, Rita, et al.
Publicado: (2009) -
A Case Report of Breast Cancer with Extensive Pulmonary Lymphovascular Tumor Emboli
por: Yang, Yaewon, et al.
Publicado: (2012) -
Breast Carcinomatous Tumoral Emboli Can Result From Encircling Lymphovasculogenesis Rather Than Lymphovascular Invasion
por: Mahooti, Sepi, et al.
Publicado: (2010) -
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers
por: Aoki, Takahiro, et al.
Publicado: (2016) -
Septic Pulmonary Emboli or Pulmonary Metastasis in a Patient with Diabetes Mellitus?
por: Wu, Meng-Yu, et al.
Publicado: (2018)